|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells.
|
31841195 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overall survival of breast cancer patients was negatively correlated with DLEU1 expression.
|
31841195 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
To explore the possible role of deleted in lymphocytic leukemia 1 (DLEU1) in regulating the metastasis of breast cancer and its underlying mechanism.
|
31841195 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The overall survival of breast cancer patients was negatively correlated with DLEU1 expression.
|
31841195 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Mounting studies have revealed that long non-coding RNA (lncRNA) deleted in lymphocytic leukemia 1 (DLEU1) positively regulated the initiation and development of various human malignant tumors.
|
31713587 |
2019 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma.
|
31713587 |
2019 |
|
Glioblastoma Multiforme
|
0.020 |
Biomarker
|
disease |
BEFREE |
Accordingly, our experimental data revealed that SP1-DLEU1-miR-4429 formed a feedback loop to promote GBM development, providing a new evidence for the role of DLEU1 in GBM.
|
31713587 |
2019 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma.
|
31713587 |
2019 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma.
|
31713587 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lncRNA deleted in lymphocytic leukemia 1 (DLEU1) has been reported to be dysregulated in cancer cells and thus associated with tumor development; however, the role of DLEU1 in renal cell carcinoma (RCC) remains unclear.
|
31702026 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
The results demonstrated that silencing DLEU1 decreased the growth capacity, migration and invasion of KETR3 and 786‑O cells.
|
31702026 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway.
|
31702026 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway.
|
31702026 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Characterizing rare and low-frequency height-associated variants in the Japanese population.
|
31562340 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
|
31407831 |
2019 |
|
Small Lymphocytic Lymphoma
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
|
31407831 |
2019 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
|
31407831 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.
|
31407831 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, rescue assays indicated that miR-671-5p inhibitor significantly reversed the effects of DLEU1 knockdown on osteosarcoma cell proliferation and invasion while restoration of DDX5 rescued the proliferation and invasion of osteosarcoma cells transfected with miR-671-5p mimics.
|
31379208 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
LncRNA DLEU1 was found to act as an oncogene in various types of cancer.
|
31379208 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
LncRNA DLEU1 was found to act as an oncogene in various types of cancer.
|
31379208 |
2019 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, DLEU1 acted as an oncogene in osteosarcoma by directly sponging miR-671-5p and regulating the expression of DDX5.
|
31379208 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, DLEU1 acted as an oncogene in osteosarcoma by directly sponging miR-671-5p and regulating the expression of DDX5.
|
31379208 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, DLEU1 acted as an oncogene in osteosarcoma by directly sponging miR-671-5p and regulating the expression of DDX5.
|
31379208 |
2019 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Functional studies revealed that knockdown of DLEU1 expression by siRNA led to decreased proliferation, migration and invasion and increased apoptosis in human glioma cells.
|
31360066 |
2019 |